Trial Profile

Non-interventional study for the generation of long term safety and efficacy data of pasireotide s.c. in patients with Cushing's disease (Post-Authorization Safety Study)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pasireotide (Primary)
Indications Pituitary ACTH hypersecretion
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals; Recordati

Most Recent Events

16 Apr 2024 Status changed from recruiting to completed.
21 Mar 2020 Planned End Date changed from 29 May 2024 to 1 May 2024.
04 Feb 2020 Planned End Date changed from 27 Sep 2023 to 29 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com